Chimeric Therapeutics, an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for CHM 2101, the company's first-in-class CDH17 CAR T cell therapy

Oncoinvent AS, a company in the clinical stage focused on advancing alpha emitter therapy for various solid cancers, has officially received approval from the U.S. Food and Drug Administration for its Investigational New Drug

Transpire Bio's commitment to Florida and the establishment of a biomanufacturing workforce in Weston. She envisioned this move as a potential opportunity to position South Florida at the forefront of the life sciences industry.

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company, has recently established an exclusive license agreement with Nippon Kayaku Co., Ltd for the marketing and distribution of their lead investigational therapy.

Biophytis SA, a biotechnology company in the clinical development stage listed on Nasdaq CM and Euronext Growth Paris, specializes in the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving

Oncternal Therapeutics, Inc, is a clinical-stage biopharmaceutical company dedicated to developing novel oncology treatments. They recently announced that the U.S. Food and Drug Administration has granted Fast Track designation for ONCT-534.

Simbec-Orion, a mid-sized Contract Research Organization, and biotx.ai, a company specializing in AI-powered causal modeling for drug development, have officially revealed their strategic partnership

ReHeva Biosciences, an innovative biopharmaceutical startup, is thrilled to announce the successful completion of its Phase I Safety Trial for its groundbreaking drug, RH324. This achievement represents a major milestone in the company's

Turbine, a computational biology company specializing in empirically validated in silico cell simulations for guiding biopharmaceutical research and development, has announced a collaborative partnership

Elektrofi, Inc., a biopharmaceutical formulation technology company specializing in strategic partnerships to revolutionize the delivery of biologic therapies, has announced a multi-target research collaboration and license agreement with Eli Lilly